Eli Lilly Raises 2026 Outlook Amid Surging GLP-1 Drug Demand
Eli Lilly has raised its revenue expectations for 2026, driven by soaring demand for its GLP-1 drugs. The company's stock jumped following the announcement, indicating continued momentum in its pharmaceutical segment.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)Sources
Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
By Jaimy Lee
Read full article →"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand Shares of Eli Lilly & Co. are rising in premarket trading after the pharmaceutical giant raised its full-year revenue forecast following a 48% jump in second-quarter sales, fueled by accelerating demand for the diabetes drug Mounjaro and the obesity treatment Zepbound. Lilly's second-quarter results topped Wall Street expectations: Adjusted earnings rose to $8.38 a share from $6.31 a year ear...
By Tyler Durden
Read full article →
